Condition: Nasopharyngeal Carcinoma · Nasopharyngeal Cancer · Nasopharyngeal Neoplasms · Sponsor: German Society for Pediatric Oncology and Hematology GPOH gGmbH
The purpose of this study is to assess whether the addition of the immune checkpoint inhibitor Nivolumab to induction chemotherapy will increase the percentage of patients with a complete response on MRI and PET after 3 cycles of induction therapy.
This description comes directly from the study's public registry record.
Helena Kerp, PhD · +49 201 74 94 96 14 · h.kerp@forschung-paediatrie.de
Tristan Römer, MD. · +49 241 80 38063 · troemer@ukaachen.de
Always discuss trial participation with your own doctor first.
| Uniklinik RWTH Aachen, Department of Internal Medicine | Aachen, Germany | Recruiting |
| Uniklinik RWTH Aachen, Division of Pediatric Hematology, Oncology, Stem Cell Transplantation | Aachen, Germany | Active Not Recruiting |
| Department of Pediatric Oncology and Hematology, Charité University Medicine Berlin | Berlin, Germany | Active Not Recruiting |
| Evangelisches Klinikum Bethel, Children's Hospital | Bielefeld, Germany | Active Not Recruiting |
| Department of Pediatric Hematology and Oncology, University Hospital | Bonn, Germany | Not Yet Recruiting |
| Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne | Cologne, Germany | Recruiting |
| Children's Hospital, Carl-Thiem Klinikum Cottbus | Cottbus, Germany | Recruiting |
| Clinic for Children and Adolescent Medicine, Klinikum Dortmund | Dortmund, Germany | Active Not Recruiting |
| Department of Internal Medicine, Klinikum Dortmund | Dortmund, Germany | Active Not Recruiting |
| Department of Pediatrics, University Hospital, Technische Universität Dresden | Dresden, Germany | Active Not Recruiting |
| Department fo Radiotherapy, University Hospital | Erlangen, Germany | Recruiting |
| Department of Pediatrics, University Hospital Erlangen | Erlangen, Germany | Active Not Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06019130